Drugs / Paclitaxel protein-bound
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03908333 | May 2019 → May 2022 | pancreatic ductal adenocarcinoma | Medical College of Wisconsin | Withdrawn | No outcome recorded Stop: Business |
| Phase 1/2 | NCT03410030 | Dec 2017 → Sep 2021 | pancreatic ductal adenocarcinoma | HonorHealth Research Institute | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Paclitaxel protein-bound | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03410030 ↗ |
| Known as | nab-paclitaxel | “The purpose of this study is to see if a treatment regimen with a combination of paclitaxel protein bound (also known as nab-paclitaxel), gemcitabine, and cisplatin when given...” NCT03410030 ↗1“combination of paclitaxel protein bound (also known as nab-paclitaxel), gemcitabine, and cisplatin” NCT03908333 ↗ |